Brazil’s regulator Anvisa rejects DRL and Cipla’s generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality
Brazil’s regulator Anvisa rejects DRL and Cipla’s generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality by Soban News (international And National News)